Tibet Dongcai CSI Hugangshen Innovative Drugs Industry ETF(159622.SZ)

Company Encyclopedia
View More
name
Tibet Dongcai CSI Hugangshen Innovative Drugs Industry ETF
159622.SZ
News
View More

Top 5 HK Stock Gainers/Losers (>100B) (12.31)

JIANGXI COPPER(00358) rose 5.36%, with a trading turnover 1.3 Billion HKD, and a year-to-date rose 280.9%. CHINA EAST AIR(00670) rose 4.92%, with a trading turnover 102.7 Million HKD, and a year-to-date rose 105.8%. GANFENGLITHIUM(01772) fell 4.85%, with a trading turnover 546.1 Million HKD, and a year-to-date rose 160.6%. MIXUE GROUP(02097) fell 4.34%, with a trading turnover 130.1 Million HKD, and a year-to-date rose 102.4%.

Top Gainers & Losers·
HK
00358
+1.87%
HK
00670
-0.19%
HK
01055
+0.69%
Top Gainers & Losers·
HK
00358
+1.87%
HK
00670
-0.19%
HK
01055
+0.69%

Sino Biopharm Enrolls First Patient in Phase III Trial of TDI01 for Pulmonary Fibrosis

Sino Biopharmaceutical Limited has enrolled the first patient in the Phase III trial of TDI01, a selective ROCK2 inhibitor for idiopathic pulmonary fibrosis (IPF). This is the first global Phase III trial for a ROCK2 inhibitor targeting IPF. TDI01 aims to address issues like vascular leakage and inflammation associated with IPF, with the goal of providing a safer treatment option. No scientific results have been shared yet; the announcement focuses on clinical development progress.

Reuters·
HK
01177
+2.91%
Reuters·
HK
01177
+2.91%

Hong Kong Stocks Retreat But Set for Solid Yearly Advance

Hong Kong stocks fell 207 points (0.8%) to 25,648, mirroring Wall Street's decline after mixed Fed minutes. However, positive China PMI data showed a rise in factory activity and service sector growth. Notable declines included Innovent Biologics (-3.2%) and Techtronic Industries (-2.2%). Despite the drop, the market is set for a 28% annual gain in 2025, bolstered by mainland liquidity and supportive policies. Trading will close early for New Year’s Eve, resuming on January 2.

Trading Economics·
HK
01801
+3.34%
Trading Economics·
HK
01801
+3.34%

Is the moat of the weight loss miracle drug collapsing? Multiple pharmaceutical companies on three major platforms may be caught in a brutal price war

Fallen from grace?

Wallstreetcn·
SZ
000963
+1.00%
Wallstreetcn·
SZ
000963
+1.00%

China’s Huadong Medicine Gains After Ministry Accepts Application for Weight-Loss Drug for Cats

Huadong Medicine's shares rose 1.3% to CNY39.06 after the Ministry of Agriculture accepted its application for a weight-loss drug for cats. The drug, a pribopeptide injection, showed promising results in clinical trials, with 72% of obese cats losing over 5% of their weight. The pet market for weight-loss drugs is expanding, with a significant number of urban cats classified as obese. Huadong aims to fill this gap with its innovative product, which targets specific receptors similar to human weight-loss drugs.

Yicai·
SZ
000963
+1.00%
Yicai·
SZ
000963
+1.00%
© 2026 Longbridge｜Disclaimer